A phase II evaluation of the efficacy and safety of R115777 (NSC702818) [tipifarnib] a non-peptidomimetic farnesyl transferase inhibitor, and trastuzumab in patients with advanced breast cancer
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2012
At a glance
- Drugs Tipifarnib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 27 Jun 2012 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 27 Jun 2012 Actual initiation date changed from Mar 2003 to Dec 2002 as reported by ClinicalTrials.gov.
- 27 Jun 2012 Actual end date (Jan 2003) added as reported by ClinicalTrials.gov.